Ana Oaknin

2010–2026 年に発表

168
論文数
33,729
被引用数
71
h 指数
153
i10 指数

被引用数

Ana Oaknin の年別被引用数1997 年: 被引用 1 件1998 年: 被引用 1 件2004 年: 被引用 1 件2007 年: 被引用 1 件2010 年: 被引用 19 件2011 年: 被引用 64 件2012 年: 被引用 64 件2013 年: 被引用 68 件2014 年: 被引用 95 件2015 年: 被引用 102 件2016 年: 被引用 141 件2017 年: 被引用 167 件2018 年: 被引用 183 件2019 年: 被引用 842 件2020 年: 被引用 1,451 件2021 年: 被引用 1,550 件2022 年: 被引用 1,616 件2023 年: 被引用 1,544 件2024 年: 被引用 2,759 件2025 年: 被引用 1,524 件2026 年: 被引用 45 件1999〜2003 年は被引用が無いため表示していません2005〜2006 年は被引用が無いため表示していません2008〜2009 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,710 件、この内訳の 19.9%中国: 引用元論文 1,908 件、この内訳の 14%イギリス: 引用元論文 933 件、この内訳の 6.9%イタリア: 引用元論文 910 件、この内訳の 6.7%フランス: 引用元論文 632 件、この内訳の 4.6%スペイン: 引用元論文 565 件、この内訳の 4.2%ドイツ: 引用元論文 525 件、この内訳の 3.9%カナダ: 引用元論文 482 件、この内訳の 3.5%日本: 引用元論文 399 件、この内訳の 2.9%オーストラリア: 引用元論文 339 件、この内訳の 2.5%オランダ: 引用元論文 301 件、この内訳の 2.2%韓国: 引用元論文 270 件、この内訳の 2%
0%19.9%その他 26.7%

分野

  • Medicine71.1%
  • Biochemistry, Genetics and Molecular Biology22.3%
  • Immunology and Microbiology3.1%
  • Computer Science0.9%
  • Engineering0.5%
  • Materials Science0.4%
  • その他1.7%

トピック

  • PARP inhibition in cancer therapy10.4%
  • Ovarian cancer diagnosis and treatment8.4%
  • Endometrial and Cervical Cancer Treatments5.7%
  • Cancer Immunotherapy and Biomarkers4.4%
  • DNA Repair Mechanisms4.1%
  • BRCA gene mutations in cancer2.9%
  • その他64.1%

共著者

全論文

検索で開く
  1. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

    著者: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 931

  2. Cervical cancer

    著者: , , , - The Lancet 2019 被引用: 2,444

  3. Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    著者: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 被引用: 2,839

  4. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James Sun, Kevin Lin, Heidi Giordano, Jonathan A. Ledermann, Martin Buck, Andrew Dean, Michael Friedländer, Jeffrey C. Goh, Paul R. Harnett, Ganessan Kichenadasse, Clare L. Scott, Hannelore Denys, Luc Dirix, Ignace Vergote, Laurie Elit, Prafull Ghatage, Amit M. Oza, Marie Plante, Diane Provencher, Johanne I. Weberpals, Stephen Welch, Anne Floquet, Laurence Gladieff, Florence Joly, Alexandra Léary, Alain Lortholary, Jean‐Pierre Lotz, Jacques Médioni, Olivier Trédan, Benoît You, Ayşe Balat, Claudia Hänle, Petra Krabisch, Tanja Neunhöffer, Martin Pölcher, Pauline Wimberger, A Amit, Svetlana Kovel, Michelle Leviov, Tamar Safra, Ronnie Shapira‐Frommer, Salomon M. Stemmer, Alessandra Bologna, Nicoletta Colombo, Domenica Lorusso, Sandro Pignata, Roberto Sabbatini, Giovanni Scambia, Stefano Tamberi, Claudio Zamagni, Peter C.C. Fong, Anne O’Donnell, Margarita Amenedo, A. Casado Herráez, Jesús García-Donás, E.M. Guerra, Ana Oaknin, Isabel Palacio, Ignacio Romero, A Sanchez, Susana Banerjee, Andrew R. Clamp, Yvette Drew, Hani Gabra, D Jackson, JA Ledermann, Iain A. McNeish, C. A. Parkinson, Melanie Powell, Carol Aghajanian ほか 17 名 - The Lancet 2017 被引用: 1,704

  5. Endometrial cancer

    著者: , , , , , , - Nature Reviews Disease Primers 2021 被引用: 691

  6. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    著者: , , , , , , , , , , , - Annals of Oncology 2022 被引用: 638

  7. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

    著者: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 372

  8. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    著者: , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2019 被引用: 840

  9. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 475

  10. Survival with Cemiplimab in Recurrent Cervical Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , George D. Yancopoulos, Israel Lowy, Melissa Mathias, Matthew G. Fury, Ana Oaknin - New England Journal of Medicine 2022 被引用: 427

  11. A decade of clinical development of PARP inhibitors in perspective

    著者: , , , , , , , , , - Annals of Oncology 2019 被引用: 730

  12. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    著者: , , , , , , , , , , - Annals of Oncology 2023 被引用: 388

  13. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Frederik Marmé, Shannon N. Westin, Iain A. McNeish, Danny Shih, Kevin K. Lin, Sandra Goble, Stephanie Hume, Keiichi Fujiwara, Rebecca Kristeleit - Journal of Clinical Oncology 2022 被引用: 384

  14. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

    著者: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2014 被引用: 1,625

  15. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin 2023 被引用: 442

  16. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sarper Toker, Stephen J. O’Keefe, Sandro Pignata, Linda Duska - The Lancet 2024 被引用: 349

  17. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2021 被引用: 292

  18. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 371

  19. Improved Survival with Bevacizumab in Advanced Cervical Cancer

    著者: , , , , , , , , , , , - New England Journal of Medicine 2014 被引用: 1,502

  20. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

    著者: , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2017 被引用: 679

  21. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carol Aghajanian, Michael A. Bookman - New England Journal of Medicine 2019 被引用: 929

  22. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sophie Abadie‐Lacourtoisie, Claudia Andreetta, Nerea Anzizar, Daiseuke Aoki, Maria-Pilar Barretina-Ginesta, Marco Johannes Battista, Charlotte Béllier, Anne Gry Bentzen, Dominique Berton, Bertrand Billemont, Line Bjørge, Maria Bjurberg, Destin Black, Alessandra Bologna, Elena Ioana Braicu, Cláudia Casanova, Radoslav Chekerov, Annick Chevalier, Juan Cueva, Bastian Czogalla, Nicolas Delanoy, Dominik Denschlag, Oscar Derke, Michael Eichbaum, Takayuki Enomoto, Carmen Esteban, Michel Fabbro, Tanja Fehm, Annamaria Ferrero, Markus C. Fleisch, Anne Floquet, Antonio Frassoldati, Lydia Gaba, Angiolo Gadducci, Yolanda García García, Elena Geuna, Eva Guerra, Lars Hanker, Anne‐Claire Hardy‐Bessard, Philipp Harter, Kosei Hasegawa, Kristina Hellman, Ana Herrero, Felix Hilpert, Dionyssios Katsaros, M. Koegel, Anthoula Koliadi, Jean‐Emmanuel Kurtz, Bjoern Lampe, Andrea Alberto Lissoni, Alain Lortholary, Giorgia Mangili, Laura Mansi, Frederik Marmé, Cara Mathews, William Mina, Shinichiro Minobe, Katherine Moxley, Shoji Nagao, Ornella Nicoletto, Koji Nishino, Hiroshi Nishio, Shin Nishio, Ana Oaknin, Michaela Onstad, Beatriz Pardo, José Alejandro Pérez Fidalgo, Carmela Pisano, Andrés Poveda, Julia Caroline Radosa ほか 21 名 - The Lancet 2023 被引用: 209

  23. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Iain A. McNeish - The Lancet Oncology 2016 被引用: 1,200

  24. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

    著者: , , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2022 被引用: 322